EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 12 (Décembre 2009) Med Sci (Paris), 25 12 (2009) 1024-1032 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1024 - 1032
Section I - De la conception à la production
DOI https://doi.org/10.1051/medsci/200925121024
Published online 15 December 2009
  1. Schneider CK. Monoclonal antibodies: regulatory challenges. Current Pharmaceutical Biotechnology 2008; 9 :431–8. [Google Scholar]
  2. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression system: an overview of the current upstream technologies. Curr Pharm Biotechnol 2008; 9 : 447–67. [Google Scholar]
  3. Seamans TC, Fries S, Beck A, et al. Cell cultivation process transfer and scale up in support of the production of early clinical supplies of an anti-IGF-1R antibody (part I). BioProcess Int 2008; 3 : 26. [Google Scholar]
  4. Beck A, Klinguer-Hamour C, Bussat MC, et al. Peptides as tools and drugs for immunotherapies. J Pept Sci 2007; 13 : 588–602. [Google Scholar]
  5. Beck A, Wagner-Rousset E, Goetsch L, et al. Therapeutic antibodies: structure assessment by mass spectrometry from screening to clinical batches. Screening Trends Drug Discov 2008; 9 : 18–20. [Google Scholar]
  6. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30. [Google Scholar]
  7. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins. Curr Pharm Biotechnol 2008; 9 : 482–501. [Google Scholar]
  8. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 : 495–7. [Google Scholar]
  9. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81 : 6851–5. [Google Scholar]
  10. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321 : 522–5. [Google Scholar]
  11. McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348 : 552–4. [Google Scholar]
  12. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368 : 856–9. [Google Scholar]
  13. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7 : 13–21. [Google Scholar]
  14. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, et al. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008; 3 : 1157–71. [Google Scholar]
  15. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008; 20 : 450–9. [Google Scholar]
  16. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20 : 436–3. [Google Scholar]
  17. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7 : 1401–13. [Google Scholar]
  18. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25 : 1369–72. [Google Scholar]
  19. Van der Neut Kolfschoten M., Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317 : 1554–7. [Google Scholar]
  20. Dillon TM, Ricci MS, Vezina C, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283 : 16206–15. [Google Scholar]
  21. Yoo EM, Wims LA, Chan LA, et al. Human IgG2 can form covalent dimers. J Immunol 2003; 170 : 3134–8. [Google Scholar]
  22. Liu YD, Chen X, Enk JZ, et al. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008; 283 : 29266–72. [Google Scholar]
  23. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20 : 460–70. [Google Scholar]
  24. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25 : 1256–64. [Google Scholar]
  25. Natsume A, In M, Takamura H, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68 : 3863–72. [Google Scholar]
  26. Angal S, King DJ, Bodmer MW, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30 : 105–8. [Google Scholar]
  27. Kai M, Motoki K, Yoshida H, et al. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor. Nat Biotechnol 2008; 26 : 209–11. [Google Scholar]
  28. Wurch T, Lowe P, Caussanel V, et al. Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation. Curr Pharm Biotechnol 2008; 9 : 502–9. [Google Scholar]
  29. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358 : 1109–17. [Google Scholar]
  30. Wagner-Rousset E, Bednarczyk A, Bussat MC, et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872 : 23–37. [Google Scholar]
  31. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6 : 1161–73. [Google Scholar]
  32. Hamilton SR, Gerngross TU. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 2007; 18 : 387–92. [Google Scholar]
  33. Anthony RM, Nimmerjahn F, Ashline DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320 : 373–6. [Google Scholar]
  34. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20 : 471–8. [Google Scholar]
  35. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008; 20 : 479–85. [Google Scholar]
  36. Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008; 7 : 641–2. [Google Scholar]
  37. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26 : 985–90. [Google Scholar]
  38. Moon JY, Kim W, Kim JH, et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J 2008; 49 : 389–99. [Google Scholar]
  39. Beck A, Bussat MC, Zorn N, et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819 : 203–18. [Google Scholar]
  40. Vlasak J, Ionescu R. Heterogeneity of Monoclonal Antibodies relvealed by charge-sensitive methods. Curr Pharm Biotechnol 2008; 9 : 468–81. [Google Scholar]
  41. Beck A, Wurch T, Corvaïa N. Editorial: therapeutic antibodies and derivatives: from the bench to the clinic. Curr Pharm Biotechnol 2008; 9 : 421–2. [Google Scholar]
  42. Swann PG, Tolnay M, Muthukkumar S, et al. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008; 20 : 493–9. [Google Scholar]
  43. Kim MS, Lee SH, Song MY, et al. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 2007; 374 : 1374–88. [Google Scholar]
  44. Aggarwal S. What’s fueling the biotech engine-2007. Nat Biotechnol 2008; 26 : 1227–33. [Google Scholar]
  45. Gires O. EpCAM, une protéine versatile impliquée dans l’oncogenèse. Med Sci (Paris) 2009; 25 : 449–50. [Google Scholar]
  46. Faye L, Champey Y. Plantes, médicaments et génétique : quelles applications pour demain ? Med Sci (Paris) 2008; 24 : 939–45. [Google Scholar]
  47. Beck A, Iver H, Reichert JM. European Medecines Agency workshop on biosimilar monoclonal antibodies Meeting Report (London, UK, July 2, 2009). mAbs-Landes Bioscience 2009; 5 : 394–416. (http://www.landesbioscience.com/journals/mabs/article/9630). [Google Scholar]
  48. Beck A, Cochet O, Wurch T. GlycoFi’s technology to control the glycosylation of recombinant therapeutic proteins. Expert Op Drug Discov 2010 (sous presse). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.